MedTrace Logo

A Phase 1 Study of CDX-0159

NCT04146129 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-07-07

No results posted yet for this study

Summary

This is a study to determine the safety of CDX-0159 in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

CDX-0159

Single dose of one of four dosages of CDX-0159

DRUG

Normal saline

Single infusion of normal saline

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-29
Primary Completion
2020-04-06
Completion
2020-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04146129 on ClinicalTrials.gov